Compare Ascendis Pharma A/S (ASND) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Fox Corp Class A — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Fox Corp Class A trades at $55.97 (market cap $21.54B). The key difference: Fox Corp Class A is the larger of the two by market cap, and Fox Corp Class A pays a 1.03% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | FOXA | |
|---|---|---|
Market Cap | $17.74B | $21.54B |
Sector | Health | Media |
52-Week High | $277.18 | $76.11 |
52-Week Low | $163.32 | $48.79 |
Enterprise Value | $18.11B | $25.51B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FOXA trades at $54.12, up 0.71% today, with a bearish technical signal despite recent earnings beats. The company reported strong 2025 results with revenue of $16.3B and net income of $2.26B, but faces headwinds from its $22B Roku acquisition. Analyst consensus remains positive with a $67.80 price target, though technical indicators show selling pressure near resistance at $55.
The outlook balances solid fundamentals against acquisition integration risks. FOXA's attractive valuation (P/E 14.24) and cash flow strength support upside potential, but investor sentiment is cautious due to leverage from the Roku deal. Near-term performance hinges on successful execution of streaming strategy amid industry consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
